- Home
- AMAL vs SNDX Comparison
AMAL vs SNDX Comparison
Compare AMAL & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMAL
- SNDX
- Stock Information
- Founded
- AMAL 1923
- SNDX 2005
- Country
- AMAL United States
- SNDX United States
- Employees
- AMAL N/A
- SNDX N/A
- Industry
- AMAL Commercial Banks
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- AMAL Finance
- SNDX Health Care
- Exchange
- AMAL Nasdaq
- SNDX Nasdaq
- Market Cap
- AMAL 900.4M
- SNDX 974.9M
- IPO Year
- AMAL 2018
- SNDX 2016
- Fundamental
- Price
- AMAL $26.72
- SNDX $11.54
- Analyst Decision
- AMAL Buy
- SNDX Strong Buy
- Analyst Count
- AMAL 4
- SNDX 10
- Target Price
- AMAL $36.13
- SNDX $36.20
- AVG Volume (30 Days)
- AMAL 262.2K
- SNDX 1.9M
- Earning Date
- AMAL 04-24-2025
- SNDX 05-07-2025
- Dividend Yield
- AMAL 2.09%
- SNDX N/A
- EPS Growth
- AMAL 20.28
- SNDX N/A
- EPS
- AMAL 3.44
- SNDX N/A
- Revenue
- AMAL $304,261,000.00
- SNDX $23,680,000.00
- Revenue This Year
- AMAL $12.20
- SNDX $286.51
- Revenue Next Year
- AMAL $13.99
- SNDX $120.86
- P/E Ratio
- AMAL $7.77
- SNDX N/A
- Revenue Growth
- AMAL 10.81
- SNDX N/A
- 52 Week Low
- AMAL $21.33
- SNDX $9.66
- 52 Week High
- AMAL $38.19
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- AMAL 38.62
- SNDX 44.37
- Support Level
- AMAL $25.17
- SNDX $9.66
- Resistance Level
- AMAL $26.67
- SNDX $11.61
- Average True Range (ATR)
- AMAL 1.22
- SNDX 1.01
- MACD
- AMAL 0.07
- SNDX 0.02
- Stochastic Oscillator
- AMAL 42.36
- SNDX 56.12
About AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.